Sqz Biotechnologies Co.

SQZ Biotechnologies Co. is a clinical-stage biotechnology company specializing in the development of novel cell therapy platforms aimed at treating cancer, autoimmune, and infectious diseases. Founded in 2013 and headquartered in Watertown, Massachusetts, the company focused on advancing its proprietary platforms such as SQZ Antigen Presenting Cells, Activating Antigen Carriers, and Tolerizing Antigen Carriers. Its lead clinical programs targeted HPV16+ advanced or metastatic solid tumors, including cervical, head-and-neck, and other related cancers, with investigational therapies like SQZ-PBMC-HPV undergoing early-phase clinical trials as both standalone and combination treatments with immuno-oncology agents. In early 2024, shareholders approved the sale of SQZ Biotechnologies' key assets and a plan for the company’s liquidation and dissolution, marking a significant transition in its corporate existence and concluding its direct market participation.